10\u2003Complete Mesocolic Excision Produces Favorable Survival Outcomes Compared to Conventional Colectomy

Abstract

\n \n \n Conventional colectomy, and the Japanese Society for Cancer of the Colon and Rectum (JSCCR) D2 Lymphadenectomy (LND2), are the standards of care for the surgical management of colon cancer. Colectomy with complete mesocolic excision (CME) and JSCCR D3 Lymphadenectomy (LND3) are alternative, and more radical procedures, that provide greater lymph nodal clearance. However, controversy exists over the long-term survival benefits of CME/LND3 over non-CME colectomies (NCME)/LND2.\n \n \n \n In this study, we performed a meta-analysis to compare the survival outcomes of CME/LND3 with NCME/LND2. Medline and Embase databases were searched for articles reporting survival outcomes of both CME/LND3 and NCME/LND2, with comparisons presented using odds ratios (OR).\n \n \n \n Ten studies were included in this analysis. Overall and disease-free survival favored CME/LND3 (3-year OS: OR\u2009=\u20091.56; CI 1.22-2.00; p\u2009=\u20090.0004, 5-year OS: OR\u2009=\u20091.29; CI 1.02-1.64, p\u2009=\u20090.03, 3-year DFS: OR\u2009=\u20091.45; CI 1.12-1.88; p\u2009=\u20090.005, 5-year DFS: OR\u2009=\u20091.61; CI 1.14-2.28; p\u2009=\u20090.007). Overall and disease-free survival rates at five years were 79.8% and 85.9%, and 74.6% and 78.0%, in the CME/LND3 and NCME/LND2 groups respectively.\n \n \n \n This is the first meta-analysis to demonstrate that CME/LND3 has superior long-term survival outcomes compared to NCME/LND2, hence a strong case can be made for incorporating CME/LND3 into standard care practice.\n